Search

Displaying results 4481 - 4490 of 10000 in total
  1. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamineCategories: Vasodilators Used in Cardiac Diseases
  2. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Glycocholic acid

    go.drugbank.com/drugs/DB02691
    Investigational

    It acts as a detergent to solubilize fats for absorption and is itself absorbed.

    Synonyms: N-choloylglycineCategories: N-substituted Glycines, Compounds used in a research, industrial, or household setting
  4. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. … It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379].

  5. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234220] It has also been observed to be efficacious independent of food intake.[A234220]

    Synonyms: IN-A001Products: KI-CAB® TABLETAS 50 MG
  6. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

  7. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).

  8. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma. … ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth.

  9. Drug

    Remikiren

    go.drugbank.com/drugs/DB00212
    Experimental

    Remikiren is an orally active, high specificity renin inhibitor.

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).